Results · Commerce & Consumer Brands

Arata reports revenue growth and expansion plans

By Startup Enthusiast · 17 February 2026

What they do

Arata sells hair care products using advanced biological research

The company grew revenue by 192% in FY25 to ₹61.06 Cr

It targets ₹160 Cr revenue within the next 12 months and launches new serums soon

Arata reported a 192% year-on-year revenue increase for the fiscal year 2025.
Revenue rose from ₹20.88 Cr in FY24 to ₹61.06 Cr in FY25.
The company generated ₹46.70 Cr in revenue between April and November 2025.
Management forecasts full-year revenue of ₹75 Cr for the current financial year.
Leadership targets a monthly revenue peak exceeding ₹9 Cr in early 2026.
The brand has set a goal to achieve ₹160 Cr in revenue within the next twelve months.
Arata is preparing to launch a new Biosciences Hair Growth Serum product line.
The company is executing a full rebrand to align with its scientific positioning.

Arata represents a shift from generic natural products to specialized biological solutions.
The rapid growth highlights strong consumer demand for clinically proven hair care.
The pivot to mitochondria-led science differentiates Arata in the crowded beauty market.
High volume sales indicate successful integration across multiple digital sales channels.

Arata originated as an alcohol-free flaxseed styling gel alternative for consumers.
The brand pivoted to develop efficacious 'Cell Rejuve' hair science technologies.
It is the first Indian brand offering mitochondria-led hair and scalp solutions.
The company maintains an in-house R&D and quality control laboratory in Delhi.
Operations include a 4K sq ft headquarters and an 11K sq ft warehouse.
The warehouse features conveyor belts and automated packaging systems for efficiency.
Arata processes over 50,000 direct-to-consumer orders every month.
B2B sales volume reaches approximately 2 Lakh units per month.
E-commerce platforms account for 38% of total sales mix in FY25.
The D2C website contributes 32% while quick commerce makes up 30%.
Products are positioned as clinically proven alternatives to conventional pharmaceuticals.